Exonate: Phase 1b/2a Trial of Exonate's Eye Drop Demonstrate Safety and Biological Activity in Treatment of DR and DME
UK-based Exonate announced data from a phase 1b/2a trial for lead candidate EXN407 demonstrating safety and tolerability of the drug candidate, a
Read full article »
Exonate focuses on the discovery and development of treatment for retinal neovascular diseases.
Read more